Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation. # # # For more information, please contact: Media contacts: Thomas Biegi Tel.: +49 (0)89 / 89927 26079 Thomas.Biegi@morphosys.com Jeanette Bressi Tel: +1 617-404-7816 jeanette.bressi@morphosys.com Investor contacts: Dr. Julia Neugebauer Tel: +49 (0)89 / 899 27 179 julia.neugebauer@morphosys.com Myles Clouston Tel: +1-857-772-0240 myles.clouston@morphosys.com References ^[1] Sarkozy C, et al. Management of relapsed/refractory DLBCL. Best Practice Research & Clinical Haematology. 2018 31:209-16. doi.org/10.1016/j.beha.2018.07.014. ^[2] Skrabek P, et al. Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma. Current Oncology. 2019 26(4): 253-265. doi.org/10.3747/co.26.5421. ^[3] Skrabek P, et al. Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma. Current Oncology. 2019 26(4): 253-265. doi.org/10.3747/co.26.5421.

-----------------------------------------------------------------------------------------------------------------------

2021-08-24 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

----------------------------------------------------------------------------------------------------------------------- 


Language:     English 
Company:      MorphoSys AG 
              Semmelweisstr. 7 
              82152 Planegg 
              Germany 
Phone:        +49 (0)89 899 27-0 
Fax:          +49 (0)89 899 27-222 
E-mail:       investors@morphosys.com 
Internet:     www.morphosys.com 
ISIN:         DE0006632003 
WKN:          663200 
Indices:      MDAX, TecDAX 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq 
EQS News ID:  1228652 
 
End of News   DGAP News Service 
=------------

1228652 2021-08-24

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1228652&application_name=news

(END) Dow Jones Newswires

August 24, 2021 16:02 ET (20:02 GMT)